Susceptibility to azoles and amphotericin B of isolates of Candida spp. Experience of a university health network, between 2004 and 2010

Abstract
Objective: To describe antifungal susceptibility testing surveillance (December 2004-September 2010) in Candida spp., for amphotericin B, fluconazole and voriconazole, at the Laboratorio de Microbiologia, Pontificia Universidad Catolica de Chile. Method: The study was performed utilizing E test and included yeasts from invasive origin and isolates in which antifimgal susceptibility testing was asked for by the patient's physician. Results: The yeasts were mainly recovered from urine samples (n: 64), blood cultures (n: 51) and secretions (n: 24). Two hundred ninety three isolates were studied: C. albicans (38%), C. glabrata (30%), C. tropicalis (11%), C. parapsilosis (10%), C. krusei (4%) and others (7%). All Candida species were 100% susceptible to amphotericin B, except C. krusei (1/12). Fluconazole's global susceptibility in C. albicans was 91.8%, but 100% in isolates from blood cultures versus 76% in isolates from urine. C. tropicalis was 93.9% susceptible to fluconazole, C. parapsilosis, 90% and C. glabrata 30.3%. C. krusei had no susceptible isolates to fluconazole. Voriconazole resistance was mainly present in C. glabrata (11.5%). Conclusions: We recommend the study of antifungal susceptibility in isolates from invasive origin, selected urine strains and C. glabrata. Fluconazole remains effective in C. albicans from blood.
Description
Keywords
Candida, drug resistance, fluconazole, voriconazole, amphotericin B, ANTIFUNGAL SUSCEPTIBILITY, INVASIVE CANDIDIASIS, FLUCONAZOLE SUSCEPTIBILITY, CASPOFUNGIN RESISTANCE, SPECIES DISTRIBUTION, BROTH MICRODILUTION, EPIDEMIOLOGY, VORICONAZOLE, THERAPY, SURVEILLANCE
Citation